Fosun Pharmaceuticals announced that on November 18, 2026, the company repurchased 1.807 million H shares through the Hong Kong Stock Exchange. The repurchase price range for each share was HK$14.6 to HK$15.1, with a total transaction amount of about HK$26.9.38 million. The repurchased shares are intended to be held as treasury shares. This repurchase accounted for 0.35% of the shares issued at the beginning of the period. After the repurchase, the company has issued 517 million H shares and has 35.23 million H shares in stock. This repurchase is based on the repurchase authorization reviewed and approved on June 16, 2026. The total number of shares that can be repurchased under this authorization is 54.9972 million shares. Up to now, 24.261,000 shares have been repurchased, accounting for 4.48% of the authorized corresponding shares. Issuance of new shares or disposal of treasury shares is prohibited for 30 days after repurchase. The suspension period ends on December 18, 2026.

Zhitongcaijing · 2d ago
Fosun Pharmaceuticals announced that on November 18, 2026, the company repurchased 1.807 million H shares through the Hong Kong Stock Exchange. The repurchase price range for each share was HK$14.6 to HK$15.1, with a total transaction amount of about HK$26.9.38 million. The repurchased shares are intended to be held as treasury shares. This repurchase accounted for 0.35% of the shares issued at the beginning of the period. After the repurchase, the company has issued 517 million H shares and has 35.23 million H shares in stock. This repurchase is based on the repurchase authorization reviewed and approved on June 16, 2026. The total number of shares that can be repurchased under this authorization is 54.9972 million shares. Up to now, 24.261,000 shares have been repurchased, accounting for 4.48% of the authorized corresponding shares. Issuance of new shares or disposal of treasury shares is prohibited for 30 days after repurchase. The suspension period ends on December 18, 2026.